Your browser is no longer supported. Please, upgrade your browser.
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E38.10 EPS (ttm)1.89 Insider Own0.10% Shs Outstand2.53B Perf Week-0.19%
Market Cap182.92B Forward P/E11.16 EPS next Y6.45 Insider Trans-0.75% Shs Float2.53B Perf Month-8.53%
Income4.80B PEG2.98 EPS next Q1.55 Inst Own74.80% Short Float1.08% Perf Quarter-5.54%
Sales47.09B P/S3.88 EPS this Y-28.00% Inst Trans-0.05% Short Ratio2.64 Perf Half Y-1.04%
Book/sh13.14 P/B5.48 EPS next Y16.60% ROA6.10% Target Price93.21 Perf Year-9.21%
Cash/sh- P/C- EPS next 5Y12.77% ROE19.40% 52W Range68.38 - 81.62 Perf YTD-7.73%
Dividend2.60 P/FCF- EPS past 5Y12.20% ROI10.80% 52W High-11.83% Beta0.44
Dividend %3.61% Quick Ratio1.10 Sales past 5Y4.00% Gross Margin68.30% 52W Low5.25% ATR1.15
Employees74000 Current Ratio1.30 Sales Q/Q4.90% Oper. Margin10.60% RSI (14)30.80 Volatility1.71% 1.46%
OptionableYes Debt/Eq0.80 EPS Q/Q-59.70% Profit Margin11.80% Rel Volume1.15 Prev Close71.93
ShortableYes LT Debt/Eq0.72 EarningsJul 29 BMO Payout116.30% Avg Volume10.38M Price71.97
Recom2.00 SMA20-4.15% SMA50-5.56% SMA200-4.08% Volume11,909,357 Change0.06%
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $85
Jul-27-21Resumed Truist Buy $92
May-20-21Downgrade Argus Buy → Hold
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Sep-21-21 10:19PM  
10:45AM  
Sep-20-21 05:45PM  
03:29PM  
03:26PM  
02:23PM  
01:42PM  
01:08PM  
07:18AM  
Sep-19-21 07:55AM  
07:30AM  
Sep-18-21 10:34AM  
09:05AM  
09:05AM  
Sep-17-21 04:41PM  
03:59PM  
03:56PM  
02:29PM  
02:09PM  
07:15AM  
Sep-16-21 11:24AM  
Sep-15-21 02:40PM  
01:51PM  
08:43AM  
08:11AM  
06:58AM  
Sep-14-21 08:38AM  
Sep-13-21 05:45PM  
02:14PM  
01:40PM  
12:13PM  
09:57AM  
Sep-12-21 07:15AM  
Sep-11-21 09:18AM  
06:05AM  
Sep-10-21 08:12AM  
07:43AM  
Sep-09-21 03:34PM  
03:28PM  
02:24PM  
06:37AM  
Sep-08-21 05:50PM  
01:37PM  
01:33PM  
10:52AM  
09:29AM  
08:36AM  
08:21AM  
06:45AM  
Sep-07-21 04:00PM  
02:40PM  
02:12PM  
10:38AM  
10:23AM  
06:45AM  
06:45AM  
Sep-03-21 01:58PM  
10:06AM  
Sep-02-21 02:18PM  
12:00PM  
Sep-01-21 05:45PM  
02:14PM  
02:02PM  
09:53AM  
09:06AM  
08:05AM  
07:23AM  
07:05AM  
06:58AM  
06:45AM  
Aug-31-21 04:05PM  
03:00PM  
01:25PM  
08:36AM  
06:06AM  
Aug-30-21 02:06PM  
12:10PM  
Aug-27-21 02:07PM  
09:16AM  
Aug-26-21 03:02PM  
06:45AM  
Aug-25-21 01:38PM  
06:45AM  
Aug-24-21 02:16PM  
07:47AM  
Aug-23-21 01:57PM  
Aug-22-21 07:19AM  
Aug-20-21 04:45PM  
02:54PM  
10:25AM  
08:23AM  
Aug-19-21 03:01PM  
02:54PM  
10:57AM  
Aug-18-21 02:06PM  
10:07AM  
09:48AM  
08:46AM  
Aug-17-21 03:19PM  
02:12AM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clyburn FrankEVP & Pres ? Human HealthMay 10Option Exercise0.0019,3240113,672May 11 02:41 PM
Clyburn FrankEVP & Pres ? Human HealthMay 10Sale78.3219,3241,513,44094,348May 11 02:41 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 04Option Exercise75.9841731,6845,662May 06 05:04 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise75.981,21292,08836,215May 06 05:02 PM
Litchfield CarolineEVP & CFOMay 04Option Exercise75.981,03978,94320,230May 06 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 04Option Exercise75.9869452,7302,612May 06 04:48 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise75.981,906144,81895,287May 06 04:40 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise74.5087565,18835,303May 04 04:50 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 03Option Exercise74.5041230,6945,387May 04 04:55 PM
Li Dean YExecutive VP & President, MRLMay 03Option Exercise74.5075055,87512,111May 04 04:57 PM
Litchfield CarolineEVP & CFOMay 03Option Exercise74.5075055,87519,544May 04 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 03Option Exercise74.5043732,5562,068May 04 05:04 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 01Option Exercise74.5062246,3391,841May 04 05:04 PM
Litchfield CarolineEVP & CFOMay 01Option Exercise74.5084062,58019,082May 04 05:01 PM
Li Dean YExecutive VP & President, MRLMay 01Option Exercise74.501,03076,73511,715May 04 04:57 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 01Option Exercise74.5056041,7205,167May 04 04:55 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise74.5090167,12434,737May 04 04:50 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale81.42280,00022,797,011411,546Nov 12 04:45 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise75.892,287173,56013,403Nov 03 04:48 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise75.894,574347,1217,624Nov 03 04:44 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise75.892,287173,56083,656Nov 03 04:55 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Option Exercise0.00251,2730422,329Oct 06 04:52 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Sale81.03251,27320,360,325171,056Oct 06 04:52 PM